8-K: Avalo Therapeutics Acquires Anti-IL-1 Antibody, Secures $185 Million in Private Funding

Avalo Therapeutics has acquired AlmataBio, gaining a Phase 2-ready anti-IL-1 antibody and securing up to $185 million in private financing.

Summary

• Avalo Therapeutics acquired AlmataBio, gaining access to AVTX-009, a Phase 2-ready anti-IL-1 monoclonal antibody.
• The acquisition was accompanied by a private placement financing of up to $185 million, with an initial investment of $115.6 million.
• Net upfront proceeds are expected to be approximately $105 million after deducting transaction costs.
• Avalo plans to develop AVTX-009 for hidradenitis suppurativa (HS), with topline results from a Phase 2 trial expected in 2026.
• The financing is expected to extend Avalos cash runway into 2027.
• The acquisition involved an exchange of Avalo common stock and preferred stock valued at approximately $15 million.
• A cash payment of $7.5 million is due to former AlmataBio stockholders upon the initial closing of the private placement investment.
• Avalo is also required to pay development milestones to the former AlmataBio stockholders, including $5 million due upon the first patient dosed in a Phase 2 trial in patients with HS for AVTX-009 and $15 million due upon the first patient dosed in a Phase 3 trial for AVTX-009.
• The private placement includes the issuance of approximately 19,900 shares of non-voting convertible preferred stock and warrants to purchase up to approximately 12.0 million shares of Avalos common stock or an equivalent amount of non-voting convertible preferred stock.
• The warrants are exercisable at $5.80 per share until the earlier of five years from issuance or 30 days after the public announcement of the first patient dosed in a Phase 2 trial of AVTX-009 in HS.
• The total number of shares of Avalo common stock outstanding would be approximately 23.4 million immediately after the closing of the transactions (excluding the exercise of the warrants).

Sentiment

Score: 8

Explanation: The document is highly positive, highlighting the strategic acquisition, strong financial backing, and potential of AVTX-009. The language used is optimistic and forward-looking, suggesting confidence in the company's future prospects.

Positives

• The acquisition of AVTX-009 provides Avalo with a promising Phase 2-ready asset.
• The private placement financing provides substantial capital to fund operations into 2027.
• AVTX-009 has a high probability of success in HS due to its target, half-life, and potency.
• The management team has a proven track record of late-stage immunology development.
• The acquisition and financing are expected to create long-term growth opportunities for Avalo.

Negatives

• The document does not explicitly state any negatives.

Risks

• The success of AVTX-009 is dependent on the outcome of clinical trials.
• The company is reliant on key personnel.
• Regulatory risks and general economic and market risks could impact the company.
• The company is reliant on investigators and enrollment of patients in clinical trials.

Future Outlook

Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS) and at least one other chronic inflammatory indication. Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund operations through this data readout and into 2027.

Management Comments

• We are thrilled to announce the acquisition of AVTX-009 and concurrent financing of up to $185 million.
• Avalo remains focused on the treatment of inflammatory conditions, and we are excited to prepare to initiate a Phase 2 trial in HS, a severe autoimmune disease with significant unmet needs.
• We believe AVTX-009, which was originally developed by Eli Lilly, has a high probability of success for the treatment of HS as evidenced by recent data readouts validating inhibition of IL-1 in this disease.
• We believe that HS is a multi-billion-dollar commercial opportunity and that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing.
• We are excited to be fully funded through our expected data readout and we appreciate the support of this outstanding investment syndicate.
• We are pleased that Avalo recognizes the promise of AVTX-009, an important potential treatment option for patients with inflammatory diseases.

Industry Context

The acquisition of AVTX-009 and the focus on HS aligns with the growing interest in developing targeted therapies for inflammatory and autoimmune diseases. The document highlights the potential of IL-1 inhibition in HS, a market with significant unmet needs and commercial potential.

Comparison to Industry Standards

• The document references a Phase 2 trial of lutikizumab (NCT05139602) which validates IL-1 targeting in HS, and notes that efficacy was comparable with other HS therapies despite a more severe patient population.
• The document also references a Phase 2 trial of bermekimab (NCT04988308) which failed to demonstrate efficacy, suggesting that not all IL-1 inhibitors are effective in HS.
• The document also references a Phase 2 trial of MAS825 (NCT03827798) which showed positive results in HS, suggesting that bispecific inhibitors of IL-1 and IL-18 may be effective.
• The document suggests that AVTX-009 may be best-in-class due to its target, half-life, and potency, which may allow for strong efficacy and convenient dosing.

Management Changes

Stakeholder Impact

• Shareholders: The acquisition and financing are expected to create long-term growth opportunities and increase shareholder value.
• Employees: The company will continue to be led by the current leadership team.
• Customers: The company is focused on developing new treatments for inflammatory conditions.
• Suppliers: The company will continue to operate in the ordinary course of business.
• Creditors: The company has secured substantial capital to fund operations.

Next Steps

• Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS).
• A Phase 2 trial in HS is planned, with topline results expected in 2026.
• Avalo intends to develop AVTX-009 in at least one other chronic inflammatory indication.
• The private placement is expected to close on March 28, 2024.

Key Dates

Keywords

AVTX-009, hidradenitis suppurativa, anti-IL-1 mAb, private placement, biotechnology, immunology, clinical trials, AlmataBio, Phase 2, financing